In a recent study published in the journal BMC Women’s Health , researchers evaluated the efficacy of clomiphene and dexamethasone in treating polycystic ovary syndrome (PCOS). PCOS is a gynecological disease affecting a substantial proportion of females of reproductive age. Affected individuals have irregular secretion of luteinizing (LH) and follicle-stimulating (FSH) hormones, as well as insulin resistance.
The disease primarily results from an increased LH-to-FSH ratio and elevated secretion of gonadotropin-releasing hormone. Nevertheless, the etiology of PCOS is complex and debatable. Clomiphene citrate has been considered the primary medication to induce ovulation in infertile PCOS patients.
Further, dexamethasone can inhibit aromatase and regulate estrogen levels. Studies suggest that a combined dexamethasone and clomiphene therapy may improve ovulation and pregnancy outcomes in PCOS patients, albeit the evidence is unclear. Study: A meta-analysis of efficacy on dexamethasone and clomiphene in the treatment of polycystic ovary syndrome patients .
Image Credit: SewCreamStudio / Shutterstock In the present study, researchers meta-analyzed the safety and efficacy of the combined clomiphene and dexamethasone treatment in PCOS patients. They searched PubMed, Cochrane Library, Embase, VIP Information Chinese Journal Service Platform, Wan Fang Medical Network, and China National Knowledge Infrastructure for relevant randomized controlled trials (RCTs) till January 2023. The.